Rubius Stops Clinical Development of RTX-134 Cell Therapy for Phenylketonuria
News
Rubius Therapeutics is discontinuing its Phase 1b trial investigating RTX-134, a potential cell therapy for people with phenylketonuria (PKU). The decision comes as the company shifts its focus to the ... Read more